Category Archives: Myocardial Infarction

This article was originally published here Int J Cardiol. 2020 Dec 8:S0167-5273(20)34245-5. Continue reading →

This article was originally published here Ann Med Surg (Lond). 2020 Nov 27;60:610-613. doi: 10.1016/j.amsu.2020.11.062 Continue reading →

With cardiovascular injury a long-term effect for COVID-19 survivors, healthcare needs a proven means of telemetry style remote cardiac monitoring. Continue reading →

The year 2021 will encompass a bigger focus on neoadjuvant and adjuvant trials, more novel molecular compounds for more select subgroups, and a migration of circulating tumor DNA (ctDNA) into a more minimal residual disease (MRD)based setting, according to Balazs Halmos, MD. 2020, despite being a terrible year as a result of COVID-19, actually has been a good year for thoracic oncology, said Halmos, a professor of medicine at Albert Einstein College of Medicine and director of the Thoracic Head and Neck Program at Montefiore Medical Center. As for next year, I think it will be hard to replicate what we've seen this year in terms of the great successes, but there are definitely a number of stories that will continue to unfold. Continue reading →

TORONTO, Dec. 16, 2020 /CNW/ -HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces updates on its filings with Health Canada for MyCare and Trinomia Continue reading →

This article was originally published here J Int Med Res. Continue reading →

This article was originally published here J Cardiovasc Pharmacol. 2020 Dec;76(6):678-683. Continue reading →

Coronary artery calcium (CAC) score as a measure of plaque burden more reliably predicts future cardiovascular (CV) risk in patients with suspected coronary disease (CAD) than whether or not the disease is obstructive, a large retrospective study suggests. Continue reading →

Please note that the text below is not a full transcript and has not been copyedited. Continue reading →

Patients with chronic lymphocytic leukemia (CLL) who received treatment with single-agent acalabrutinib (Calquence) experienced a low incidence of cardiac toxicities leading to treatment discontinuation, according to data from a pooled analysis across 4 clinical trials presented during the 2020 ASH Annual Meeting & Exposition.1 Results showed that 17% (n = 129) of 762 patients with CLL who received treatment with the second-generation BTK inhibitor as a monotherapy experienced cardiac toxicity of any grade at a median follow-up of 25.9 months, which led to treatment discontinuation in 7 patients (0.9%). Continue reading →